Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy

Authors :: John C. Morris
Patrick Hwu
Matthew S. Block
Sacha Gnjatic
H. Lu
Chet Bohac
Khanh Tu Do
Robin L. Jones
Seth M. Pollack
Shanta Chawla
Neeta Somaiah
Mihaela Druta
Joseph Kim
Source :: Annals of Oncology. 29:viii578
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
Immune system
business.industry
Internal medicine
Soft tissue sarcoma
medicine
Overall survival
Hematology
NY-ESO-1
medicine.disease
business

Full Text Access

Tools